Efficacy News and Research

RSS

Peptide receptor radiolabeled therapy shows promise against neuroendocrine tumors

According to new Dutch research featured in the September issue of The Journal of Nuclear Medicine, a peptide receptor radiolabeled therapy (PRRT), [177Lu-DOTA0,Tyr3]Octreotate (177Lu-octreotate), is effective not only in decreasing tumor size but also in reducing the severity of side effects that often accompany a cancer diagnosis.

22 Sep 2011

Combination of SRIs and cognitive behavior therapy reduces pediatric OCD symptoms

Children and teens with obsessive-compulsive disorder (OCD) who were receiving some benefit from treatment with medication had a significantly greater reduction in OCD symptoms with the addition of cognitive behavior therapy, according to a study in the September 21 issue of JAMA.

21 Sep 2011

HRPR before PCI procedures linked to increased risk of ischemic event in ACS patients

Among patients with acute coronary syndromes undergoing a procedure such as angioplasty, those who received platelet function tests before receiving antithrombotic therapy to determine appropriate clopidogrel dosing and who had high residual platelet reactivity were at an increased risk of an ischemic event at short- and long-term follow-up of up to 2 years, according to a study in the September 21 issue of JAMA.

21 Sep 2011

Positive data from InVivo's biomaterial scaffold implant preclinical study on acute SCI

InVivo Therapeutics Holdings Corp., a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that in a rodent contusion model of SCI the Company's proprietary biopolymer scaffold showed positive preliminary data that indicate a therapeutic effect.

21 Sep 2011

Clinical trial to evaluate TAU's stem cell technology for ALS

The ability to produce neuroprotectors, proteins that protect the human brain against neurodegenerative disorders such as Parkinson's and ALS, is the holy grail of brain research. A technology developed at Tel Aviv University does just that, and it's now out of the lab and in hospitals to begin clinical trials with patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

21 Sep 2011

Enrollment commences in Boehringer Ingelheim's TOviTO Phase III combination trial for COPD

Boehringer Ingelheim today announced enrolment has commenced in its TOviTO Phase III clinical trial program. It will investigate tiotropium plus olodaterol in a once-daily fixed-dose combination for the treatment of chronic obstructive pulmonary disease.

21 Sep 2011

UNC's new nanoparticle shows potential for cancer chemotherapy

A new type of nanoparticle developed in the laboratories at the University of North Carolina has shown potential for more effective delivery of chemotherapy to treat cancer.

21 Sep 2011

Antivirals from shark cartilage compound squalamine

A unique compound originally isolated from sharks could prove to be a promising treatment for hepatitis B and C and other viral diseases, researchers say. Known as squalamine, the drug has not yet been tested as an antiviral agent in humans, but it has been given to hundreds of people enrolled in clinical trials designed to test its usefulness for other conditions. Researchers say they hope to begin human trials to test the compound’s antiviral activity within the next year.

21 Sep 2011

Positive results from Orexo's OX219 clinical study on opioid dependence

Orexo AB (STO:ORX) today announced that it has obtained positive results in a clinical study with OX219, which is being developed for the treatment of opioid dependence.

21 Sep 2011

Matrix receives FDA's tentative approval for novel co-packaged version of HIV/AIDS therapy

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) through the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine / Tenofovir Disoproxil Fumarate Tablets, 300 mg/300 mg, co-packaged with Nevirapine Tablets, 200 mg.

21 Sep 2011

Risk factors for variety of complications following spine surgery

In the last 20 years, due to diagnostic and surgical advances, more and more patients have become appropriate candidates for spine surgery, and the number of these procedures performed has risen significantly. While medical experts acknowledge the potential benefits of spine surgery, they also understand that complications can reduce the success in the short and long term.

21 Sep 2011

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Silence Therapeutics Plc, a leading international RNAi therapeutics company, today provides a corporate update and announces its interim results for the six months ended 30 June 2011.

21 Sep 2011

FSS initiates FlexStent clinical trial for treatment of peripheral arterial disease

Flexible Stenting Solutions Inc. announced today the successful treatment of the first two patients enrolled in the OPEN (Evaluation of Safety and Efficacy of the FlexStent FemorOPopliteal Self-Expanding StENt System) clinical trial.

21 Sep 2011

Exercise helps teens quit smoking

Research has shown that a program that combines counseling with physical activity may offer teens a more effective way to stop smoking. Less than 5 percent of those who were assigned to a brief smoking cessation intervention had quit smoking after three months. But, in the group of teens that received smoking cessation counseling coupled with physical activity, almost 14 percent were off cigarettes at the three-month mark. And, the findings were most dramatic for boys. Nearly a quarter of the boys in the combination group had quit smoking at the end of three months.

20 Sep 2011

U-M Professor to review data from three prominent studies on heart failure

Roughly 5 million people in the United States live with heart failure, a condition in which the heart is unable to pump blood around the body effectively. The causes and types of heart failure vary greatly, and treatment must be tailored to each patient. In some cases, doctors will prescribe a class of diuretic drugs called aldosterone antagonists.

20 Sep 2011

University of Colorado, SuviCa complete license agreement for CU cancer drug screening technology

SuviCa Inc. of Boulder and the University of Colorado recently completed an exclusive license agreement for a CU drug screening technology to identify novel therapies for cancer.

20 Sep 2011

BIOTRONIK completes enrollment in Passeo-18 Lux DEB catheter clinical study for PAD

BIOTRONIK, a leading European manufacturer of therapy solutions for vascular intervention, announced the completion of enrollment in the BIOLUX P-I - a clinical study investigating the use of a drug-eluting balloon (DEB) catheter, a promising new approach to treating disease in the more challenging peripheral vascular anatomy.

20 Sep 2011

Top-line data from Santarus' budesonide MMX extended use study on ulcerative colitis

Santarus, Inc., a specialty biopharmaceutical company, today announced that analysis of top-line safety data from a double blind, multicenter 12-month extended use study in patients treated daily with either the investigational drug budesonide MMX 6 mg or placebo will be provided as support for the company's planned submission of a New Drug Application (NDA) for budesonide MMX 9 mg to the U.S. Food and Drug Administration (FDA) for the induction of remission of mild or moderate active ulcerative colitis.

20 Sep 2011

Powerful new antibiotic treatment for MRSA and C. difficile bugs

MGB Biopharma, a biopharmaceutical company which has licensed technology from the University of Strathclyde in Glasgow, Scotland, is developing a powerful new antibiotic treatment for resistant infections including the deadly MRSA and Clostridium difficile (C. diff.) bugs.

20 Sep 2011

Keryx completes enrollment in Zerenex Phase 3 long-term study for hyperphosphatemia

Keryx Biopharmaceuticals today announced completion of patient enrollment in the long-term study component of its Phase 3 registration program of Zerenex, the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.

20 Sep 2011

Efficacy News and Research

Peptide receptor radiolabeled therapy shows promise against neuroendocrine tumors

Combination of SRIs and cognitive behavior therapy reduces pediatric OCD symptoms

HRPR before PCI procedures linked to increased risk of ischemic event in ACS patients

Positive data from InVivo's biomaterial scaffold implant preclinical study on acute SCI

Clinical trial to evaluate TAU's stem cell technology for ALS

Enrollment commences in Boehringer Ingelheim's TOviTO Phase III combination trial for COPD

UNC's new nanoparticle shows potential for cancer chemotherapy

Antivirals from shark cartilage compound squalamine

Positive results from Orexo's OX219 clinical study on opioid dependence

Matrix receives FDA's tentative approval for novel co-packaged version of HIV/AIDS therapy

Risk factors for variety of complications following spine surgery

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

FSS initiates FlexStent clinical trial for treatment of peripheral arterial disease

Exercise helps teens quit smoking

U-M Professor to review data from three prominent studies on heart failure

University of Colorado, SuviCa complete license agreement for CU cancer drug screening technology

BIOTRONIK completes enrollment in Passeo-18 Lux DEB catheter clinical study for PAD

Top-line data from Santarus' budesonide MMX extended use study on ulcerative colitis

Powerful new antibiotic treatment for MRSA and C. difficile bugs

Keryx completes enrollment in Zerenex Phase 3 long-term study for hyperphosphatemia

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News